Order results by:
| Issue | Title | |
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... with the Oswestry low back pain disability questionnaire, converted into utilities and transformed into quality ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| "... Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... -effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
| Vol 5, No 2 (2012) | METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES | Abstract similar documents |
| R. I. Yagudina, I. V. Sorokovikov | ||
| "... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... полного цитогенетического ответа (ПЦО) на протяжении одного года из расчета на одного пациента с ХФ ХМЛ ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
| M. V. Protsenko | ||
| "... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..." | ||
| Vol 7, No 2 (2014) | CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM | Abstract similar documents |
| I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek | ||
| "... -effectiveness” and “cost-utility” analyses have been used. The target population of patients suffering from ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..." | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... cost-effectiveness standard, it was 1,748,623.36 Rub for QALY; according to the method ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... in the R environment was carried out based on the keywords “health economic”, “DALY”, “QALY” in the CRAN ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... gained (LYGs) and 1.12 quality-adjusted life years (QALYs) per 1 patient during lifelong therapy ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... ) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... period of the analysis was 5 years. Quality-adjusted life year (QALY) was used as an efficiency criterion ..." | ||
| Vol 12, No 3 (2019) | Approaches to assessing the demand for medical personnel in the Russian Federation | Abstract similar documents |
| S. N. Tishkina , T. G. Alkhasov , D. V. Lukyantseva , T. P. Bezdenezhnykh | ||
| "... которых относятся расчет потребности во врачебных кадрах и мероприятия по привлечению кадров (целевые ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... of life years gained (LYG) and quality-adjusted life years (QALY) were calculated. Results were compared ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| Vol 13, No 4 (2020) | Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model | Abstract similar documents |
| V. V. Omelyanovsky, T. V. Semenova, D. V. Lukyantseva, D. V. Fedyaev, E. A. Shalaeva | ||
| "... Цель. Определение и апробация подходов к разработке методики расчета потребности во врачебных ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..." | ||
| Vol 15, No 3 (2022) | Economic burden of the novel coronavirus infection: a systematic review | Abstract similar documents |
| V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva | ||
| "... of quality-adjusted life years lost (QALY) (66.3%), 37.6% of the studies are based on the results ..." | ||
| Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... унифицированной методологии для расчета таких затрат, обеспечивающей прозрачность и объективность данных о ..." | ||
| Vol 17, No 4 (2024) | Standardized methodology for calculating the cost of medical care funded by government sources | Abstract similar documents |
| M. A. Sdvizhkova, S. A. Kovaleva, D. V. Fedyaev, V. V. Omelyanovskiy | ||
| "... стоимости МП – ключевой инструмент, влияющий на эффективность системы. Однако существующие методики расчета ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... years, and the model cycle was 1 year. The outcomes used were quality-adjusted life years (QALY), life ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... and quality-adjusted life years (QALY). Primary prevention model was focused on patients after myocardial ..." | ||
| Vol 17, No 2 (2024) | Approaches to determining the cost of laboratory tests | Abstract similar documents |
| I. I. Khayrullin, V. V. Omelyanovskiy, R. V. Gostishchev, O. A. Sukhorukikh, S. A. Kovaleva, B. G. Gorodetsky | ||
| "... : провести обзор методов расчета себестоимости лабораторных исследований. Материал и методы. Исследование ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... pharmacoeconomic analyses: «cost – effectiveness,» «cost – utility» and « budget impact». Analysis included ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... , quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third ..." | ||
| Vol 6, No 1 (2013) | THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION | Abstract similar documents |
| A. Yu. Kulikov, Yu. L. Akimova | ||
| "... вакцинопрофилактики. Приведены критерии выбора показателей эффективности для различных типов вакцин, расчеты затрат на ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... анализ «затраты-полезность» в соответствии с рекомендациями Рабочей группы по оценке затратной ..." | ||
| Vol 18, No 2 (2025) | Analysis of fatty acid profiles of micronutrients and pharmaceuticals based on omega-3 polyunsaturated fatty acid extracts from natural sources | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. A. Garanin | ||
| "... . Подтверждена полезность предлагаемого нами коэффициента стандартизации препаратов, оценивающего соответствие ..." | ||
| Vol 10, No 4 (2017) | THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE | Abstract similar documents |
| Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva | ||
| "... . Структура стандарта обеспечивает возможность расчета затрат на реализацию ПГГ, однако опыт работы над ..." | ||
| Vol 17, No 2 (2024) | Methodology of forming a model of diagnosis-related groups for cases of medical care using surgery performed by laparoscopic access | Abstract similar documents |
| I. A. Zheleznyakova, O. A. Volkova, E. I. Rumiantseva, I. A. Mikhailov, D. V. Fedyaev, A. V. Zuev, O. S. Plakhotnik, G. V. Trifonova, T. S. Vakhrusheva, E. S. Samsonova, V. V. Omelyanovskiy | ||
| "... помощи (МП) и необходимость единообразия расчетов потребовали выработки единого подхода к формированию ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... в статье представлены результаты расчета необходимых финансовых затрат на лекарственное ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..." | ||
| Vol 8, No 4 (2015) | HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS | Abstract similar documents |
| N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova | ||
| "... влияния внешних факторов; 3) расчет скорректированной оценки эффективности без учета влияния внешних ..." | ||
| Vol 7, No 2 (2014) | THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID | Abstract similar documents |
| K. V. Danilova, I. M. Razdorskaya | ||
| "... концептуальный подход, включающий анализ производственного признака, стоимостной анализ, методика расчета ..." | ||
| Vol 13, No 3 (2020) | The evaluation of the balance of standard rates within the program on state guarantees to deliver free medical care to the citizens of the Russian Federation | Abstract similar documents |
| D. V. Fedyaev, S. A. Kovaleva, K. V. Gerasimova | ||
| "... медицинской помощи на примере расчета Программы государственных гарантий бесплатного оказания гражданам ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... . anaplastic lymphoma kinase, ALK) немелкоклеточным раком легкого (НМРЛ). Материал и методы. При расчетах ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... ранее в РФ не рассчитывались. Цель. Расчет социо-экономического бремени СМА в РФ для все, популяции ..." | ||
| 1 - 50 of 108 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
